Entropy Technologies LP Acquires Shares of 29,913 Insulet Corporation $PODD

Entropy Technologies LP bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the first quarter, HoldingsChannel reports. The institutional investor bought 29,913 shares of the medical instruments supplier’s stock, valued at approximately $6,277,000.

Other large investors also recently modified their holdings of the company. NewEdge Advisors LLC increased its position in shares of Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 64 shares during the period. Cresset Asset Management LLC raised its stake in Insulet by 7.3% in the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 177 shares in the last quarter. Cerity Partners LLC lifted its position in Insulet by 68.7% during the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock worth $5,423,000 after purchasing an additional 7,030 shares during the period. Sei Investments Co. lifted its position in Insulet by 27.4% during the second quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after purchasing an additional 29,584 shares during the period. Finally, Treasurer of the State of North Carolina grew its stake in Insulet by 2.5% during the second quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after buying an additional 791 shares in the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the topic of several recent analyst reports. William Blair assumed coverage on shares of Insulet in a report on Wednesday, May 20th. They issued an “outperform” rating on the stock. UBS Group set a $219.00 price target on shares of Insulet in a report on Thursday, June 11th. Citigroup increased their price target on shares of Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Barclays decreased their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Finally, TD Cowen lowered their price objective on shares of Insulet from $379.00 to $294.00 and set a “hold” rating for the company in a research report on Monday, June 1st. Twenty-two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $235.25.

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.36% of the company’s stock.

Insulet Stock Up 3.1%

PODD stock opened at $163.26 on Friday. The firm has a 50-day moving average price of $154.09 and a 200-day moving average price of $202.61. Insulet Corporation has a 12 month low of $138.79 and a 12 month high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $11.31 billion, a P/E ratio of 37.97, a price-to-earnings-growth ratio of 1.11 and a beta of 1.11.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts anticipate that Insulet Corporation will post 6.45 EPS for the current fiscal year.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: No meaningful positive company-specific catalysts were reported in the latest batch of news.
• Neutral Sentiment: Short-interest data showed 0 shares reported short as of July 24, with a 0.0-day days-to-cover ratio, offering little actionable insight from that update.
• Negative Sentiment: Multiple law firms, including Rosen, Schall, Glancy Prongay, Pomerantz, Bernstein Liebhard, Faruqi & Faruqi, and others, announced or promoted securities class actions against Insulet, which can weigh on investor confidence. Article link
• Negative Sentiment: The lawsuits allege Insulet made misleading statements about manufacturing quality and safety issues, including problems at its Acton facility and flawed pods, suggesting potential reputational and legal overhang for the stock. Article link

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.